Aspirin non-responder status in patients with recurrent cerebral ischemic attacks

Journal of Neurology

Volumn 250, Issue 1, 2003, Pages 63-66

  Grundmann, K ^a   Jaschonek, K ^a   Kleine, B ^a   Dichgans, J ^a   Topka, H ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b KLINIKUM BOGENHAUSEN   (Germany)

Author keywords

Antiplatelet therapy; Aspirin; Cerebral ischaemia; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANTITHROMBOCYTIC AGENT; COLLAGEN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; QUANTITATIVE ANALYSIS; SECONDARY PREVENTION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TRANSIENT ISCHEMIC ATTACK; TREATMENT FAILURE;

AGED; ASPIRIN; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RECURRENCE;

EID: 0037276966     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-003-0954-y     Document Type: Article

References (16)

1. Buchanan MR, Brister SJ (1995) Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 11:221-227
2. Buchanan MR, Schwartz L, Bourassa M, Brister SJ, Peniston CM (2000) Results of the BRAT study - a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 16:1385-1390
3. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86
4. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105:1650-1655
5. Fressinaud E, Veyradier A, Sigaud M, Boyer-Neumann C, Le Boterff C, Meyer D (1999) Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates. Br J Haematol 106:777-783
6. Grotemeyer KH (1991) Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 63:587-593
7. Grotemeyer KH, Scharafinski HW, Husstedt IW (1993) Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 71:397-403
8. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230-235
9. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ (1998) PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 24-195-202
10. Marshall PW, Williams AJ, Dixon RM, Growcott JW, Warburton S, Armstrong J, et al. (1997) A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA- 100, in healthy volunteers. Br J Clin Pharmacol 44:151-155
11. Mehta SR, Yusuf S (2000) The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 21:2033-2041
12. Pappas JM, Westengard JC, Bull BS (1994) Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med 11 (8):801-804
13. Peters AJ, Borries M, Gradaus F, Jax TW, Schoebel FC, Strauer BE (2001) In vitro bleeding test with PFA-100 - aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease. J Thromb Thrombolysis 12:263-272
14. Poggio ED, Kotke-Marchant K, Welsh PA, Brooks LM, De la Rosa LR, Topol EJ (1999) The prevalence of aspirin resistance in cardiac patients as measured by platelet aggregation and the PFA-100. J Am Coll Cardiol 33:1104-1168
15. Stiegler H, Fischer Y, Niederau C, Schoebel FC, Borries M, Strauer BE, Leschke M, Reinauer H (1999) Evidence for variable platelet response to low-dose ASA in patients with coronary artery disease. J Am Coll Cardiol 33:1104-1168
16. Tarjan J, Salamon A, Jager R, Poor F, Barczi V, Dinnyes J, Hamvas J, Kinczel A, Pal A, Blasko G (1999) The rate of acetylsalicylic acid non-respondents among patients hospitalized for acute coronary disease, previously undergoing secondary salicylic acid prophylaxis. Orv Hetil 140:2339-2343